Introduction
With 1.15 million new cases each year, breast cancer is
the most common form of cancer among women worldwide
[1]. Patients with non-metastatic breast cancer are
treated surgically with or without adjuvant therapy.
Adjuvant treatments are only indicated if they significantly
reduce the risk for recurrence. Risk assessment is
of utmost importance because of the well-known side
effects of adjuvant treatment and is being conducted by
means of TNM classification and differentiation grade
complemented by estrogen and progesterone receptor
status, Her2neu expression and peritumoral vascular
invasion [2-6].